Form 4: Elanco CEO Jeffrey Simmons Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Elanco Animal Health CEO Jeffrey Simmons reports acquisition and disposal of company stock, including corrections to previous filings and participation in the Employee Stock Purchase Plan.
Summary
- Jeffrey N. Simmons, CEO and Director of Elanco Animal Health Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- On February 19, 2025, Simmons acquired 449,408 shares of common stock at $0 and disposed of 195,840 shares at $11.24.
- These transactions resulted in Simmons directly owning 1,612,848 shares and indirectly owning 145,000 shares through a revocable trust.
- The filing also corrects the number of shares purchased under Elanco's Employee Stock Purchase Plan on December 30, 2022, June 30, 2023, and April 30, 2024, by deducting 825 shares.
- Simmons acquired 1,751 shares on January 31, 2025, under the Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing primarily reports routine transactions related to stock compensation and employee stock purchase plans. The disposal of shares is offset by the acquisition of shares through the employee stock purchase plan.
Positives
- The CEO's participation in the Employee Stock Purchase Plan demonstrates confidence in the company.
- Increased direct ownership of shares by the CEO can be seen as a positive sign.
Negatives
- The disposal of 195,840 shares by the CEO could be interpreted negatively by some investors, although it may be part of a planned diversification strategy or tax planning.
Risks
- While not inherently a risk, significant changes in insider ownership can sometimes create uncertainty in the market.
Industry Context
Insider trading activity is always closely watched in the animal health industry, as it can provide insights into management's perspective on the company's future prospects. Form 4 filings are a routine part of regulatory compliance for company executives.
Comparison to Industry Standards
- Monitoring insider transactions is a standard practice across publicly traded companies, including Elanco's competitors like Zoetis and Merck Animal Health.
- Comparing the volume and frequency of insider transactions at Elanco to those of its peers can provide a broader context for assessing the significance of these filings.
- For example, if Zoetis' CEO consistently purchases shares while Elanco's CEO is selling, it could signal differing outlooks on company performance.
Stakeholder Impact
- Shareholders may be interested in the CEO's trading activity as an indicator of confidence in the company's performance.
- Employees participating in the Employee Stock Purchase Plan are directly affected by the share price and the terms of the plan.
Key Dates
| Date | Description |
|---|---|
| December 30, 2022 | Date of Employee Stock Purchase Plan share purchase (corrected) |
| June 30, 2023 | Date of Employee Stock Purchase Plan share purchase (corrected) |
| April 30, 2024 | Date of Employee Stock Purchase Plan share purchase (corrected) |
| January 31, 2025 | Date of Employee Stock Purchase Plan share acquisition |
| February 19, 2025 | Date of stock acquisition and disposal |
| February 21, 2025 | Date of Form 4 filing |
Keywords
Elanco, Jeffrey Simmons, insider trading, beneficial ownership, Form 4, stock, Employee Stock Purchase Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.